Biotech's Flying Under The Radar

LAS VEGAS, December 6, 2017 /PRNewswire/ --

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments in biotechnology causing some of the smaller, more innovative companies to fly under the radar of biotech investors. Investors are constantly inundated with information and news about the biggest biotech companies in the market. With such a large focus on the biggest companies, smaller companies with huge potential are often ignored and undiscovered.

Getting to know the small, innovative biotech companies is key for investors as they can have the largest pay off. Big biotech stocks have gone nowhere, or declined over the last few years Sanofi, Pfizer, and Bristol-Meyers. One issue of the larger companies dominating the market is they tend to develop "me too" drugs, drugs chemically related to another prototype or other compound already created and on the market. "Me too" drugs lack pricing power.

Let's take a look at a few smaller, micro biotech's that are currently flying under the radar of investors. These companies are important to follow as they have exponential growth potential and are working on new and innovative drugs: Propanc Biopharma, Inc. (OTC: PPCB), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), AEterna Zentaris Inc. (NASDAQ: AEZS), Geron Corporation (NASDAQ: GERN), and Esperion Therapeutics, Inc. (NASDAQ: ESPR).

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: $1.143, current share price: $.17 

PPCB is one such company, flying significantly under the radar. PPCB is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. PPCB had a huge announcement earlier this week… The 10^th Annual LD Micro Main Event is scheduled for December 7^th at the Luxe Sunset Boulevard Hotel in Los Angeles, CA and PPCB will be presenting. They'll be discussing the Company's future plans and operations and its focus on the anticipated milestones of its lead product, PRP, as it heads toward First-In-Human studies in 2018. PRP is a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. This event is the largest independent conference for small/microcap companies featuring 240 other companies. Companies invited to present at LD Micro's Main Event are unique and on the rise. This means big things are on the horizon for PPCB.

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Market Cap: $372.888M, current share price: $4.41 

Another small biopharma to keep a look out for is CPRX. The Company is focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. Earlier this week, the Company announced positive results from a second Phase 3 clinical trial of Firdapse® used for the symptomatic treatment of Lambert-Eaten myasthenic syndrome (LEMS). You'll want to keep a look out as CPRX continues to announce results from their clinical trials.

AEterna Zentaris Inc. (NASDAQ: AEZS)

Market Cap: $32.246M, current share price: $1.9655 

AEZS, announced earlier this week that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of adult growth hormone deficiency (AGHD) has been accepted by the European Medicines Agency (EMA) for regulatory review. Macrilen™, an orally available ghrelin agonist, stimulates the secretion of growth hormone from the pituitary gland. AEZS is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. These inventions could create potential for the larger companies to create into "me too" drugs.

Geron Corporation (NASDAQ: GERN)

Market Cap: $308.114M, current share price: $1.93 

Just last week, GERN announced that the first patient has been dosed in the expanded Part 1 of IMerge. This company is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The first patient dose is part of an ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are refractory or resistant to treatment with an erythropoiesis stimulating agent (ESA). As you can see by the Company highlights, each biotech is creating solutions for different diseases.

Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Market Cap: $1.632B, current share price: $62.29 

Although a larger company than the others in this article, it's helpful to know that earlier this month ESPR participated in an analyst-led fireside chat with investors at the Stifel 2017 Healthcare Conference in New York City. ESPR develops and commercializes convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Keeping up with some of the mid-sized biotech's helps investors recognize where the smaller to mid-sized companies fair within the market.

Content Provided By: Microcap Speculators

Email: [email protected]

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

For Full Legal Disclaimer Click Here.

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure:  Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact
FN Media Group LLC
e-mail:  [email protected]
+1-(954)345-0611

SOURCE MicroCapSpeculators.com